Osborn Williams & Donohoe LLC increased its holdings in McKesson Co. (NYSE:MCK) by 19.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,494 shares of the company’s stock after acquiring an additional 743 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in McKesson were worth $513,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also made changes to their positions in the stock. Norges Bank bought a new stake in McKesson in the 4th quarter worth about $215,791,000. Standard Life Aberdeen plc increased its holdings in McKesson by 16.7% in the 4th quarter. Standard Life Aberdeen plc now owns 288,482 shares of the company’s stock worth $32,039,000 after buying an additional 41,289 shares in the last quarter. Northern Trust Corp increased its holdings in McKesson by 1.3% in the 4th quarter. Northern Trust Corp now owns 2,369,712 shares of the company’s stock worth $261,783,000 after buying an additional 30,134 shares in the last quarter. Segall Bryant & Hamill LLC increased its holdings in McKesson by 7.5% in the 4th quarter. Segall Bryant & Hamill LLC now owns 2,861 shares of the company’s stock worth $316,000 after buying an additional 200 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in McKesson by 2.3% in the 4th quarter. BlackRock Inc. now owns 15,773,706 shares of the company’s stock worth $1,742,522,000 after buying an additional 358,982 shares in the last quarter. 85.88% of the stock is owned by institutional investors.
Shares of MCK stock traded up $0.83 during trading hours on Friday, reaching $129.92. 952,367 shares of the company traded hands, compared to its average volume of 1,538,221. McKesson Co. has a 12-month low of $106.11 and a 12-month high of $151.24. The company has a quick ratio of 0.58, a current ratio of 1.02 and a debt-to-equity ratio of 0.88. The stock has a market cap of $24.38 billion, a P/E ratio of 9.57, a PEG ratio of 1.29 and a beta of 1.23.
McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $3.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.66 by $0.03. McKesson had a return on equity of 29.02% and a net margin of 0.02%. The firm had revenue of $52.43 billion for the quarter, compared to analysts’ expectations of $53.14 billion. During the same period in the previous year, the firm earned $3.49 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis. On average, equities research analysts expect that McKesson Co. will post 14.15 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Monday, June 3rd will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, May 31st. This represents a $1.56 dividend on an annualized basis and a yield of 1.20%. McKesson’s dividend payout ratio is presently 11.50%.
In related news, EVP Lori A. Schechter sold 2,766 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $133.59, for a total value of $369,509.94. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.87% of the stock is currently owned by insiders.
Several research firms recently commented on MCK. Zacks Investment Research downgraded McKesson from a “hold” rating to a “sell” rating in a report on Thursday, May 2nd. Wolfe Research began coverage on McKesson in a research note on Tuesday, April 2nd. They set an “outperform” rating for the company. ValuEngine upgraded McKesson from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 8th. Barclays restated a “hold” rating and set a $130.00 price target on shares of McKesson in a research note on Friday, February 1st. Finally, Deutsche Bank upgraded McKesson from a “sell” rating to a “hold” rating and set a $175.00 price target for the company in a research note on Friday, January 25th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the stock. McKesson presently has a consensus rating of “Hold” and a consensus target price of $134.90.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Sundance Herald and is owned by of Sundance Herald. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://sundanceherald.com/2019/05/24/mckesson-co-mck-shares-bought-by-osborn-williams-donohoe-llc.html.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.